Surgeon seeks court order to stop woman selling JU22 skincare after share-sale dispute

Key Highlights:
Introduction
What the dispute says: facts, figures and immediate claims
How trademark ownership affects control over products and sales
Judicial protest and immediate remedies: what the plaintiffs can realistically pursue
Stock, payment mechanics and retention of title: why the numbers matter
Why clinical settings and cosmetics elevate reputational risk
Likely legal paths and timelines
Commercial and reputational consequences for both parties
Preventive steps companies and prospective buyers should take
Cross-border trademark registrations: scope and enforcement challenges
Practical steps for clinics, retailers and consumers who face a brand dispute
How courts balance rights: sample legal considerations
Possible defenses and counterarguments the respondent may raise
Negotiation and settlement options that can resolve the matter quickly
What this case signals to investors and brand managers in the cosmetics sector
Checklist: drafting a sale agreement for a clinical skincare brand
Final observations on risk management and reputational stewardship
FAQ

Key Highlights:

A medical surgeon and his company filed a judicial protest demanding the respondent cease promoting and selling JU22 skincare products after alleged failures to complete a share-and-trademark purchase worth €80,000 plus stock consideration.
The dispute raises core legal issues: ownership and transfer of trademarks, enforceability of sale agreements, retention of title for stock, and immediate remedies such as injunctive relief to prevent further use of the brand.

Introduction

A contractual dispute over a cosmetic brand and unpaid purchase consideration has escalated into a formal legal confrontation. GS Regenerative Medical and Beauty Services Ltd, represented by surgeon Giovanni Scornavacca, lodged a judicial protest against Denise Marston after she allegedly failed to complete payments for the purchase of JU22 Skincare Technologies. The contested assets include 50 percent of company shares and a registered trademark used for aesthetic and beauty products, plus scientific study rights tied to those products. The plaintiffs assert unpaid sums and ongoing use of the brand by the respondent, and they have warned of further court action to halt what they describe as unauthorized promotion and sale.

This case spotlights common pitfalls in transfers of cosmetic brands and stock, and it illustrates how quickly commercial disagreements can turn into disputes over intellectual property and business control. The following analysis unpacks the facts as presented, explains the legal levers at play, outlines likely next steps, and sets out practical guidance for founders, buyers and practitioners who deal with brand transfers, stock payments and clinical distribution of cosmetics.

What the dispute says: facts, figures and immediate claims

The reported agreement was executed on October 24, 2024. It involved two parties splitting ownership of JU22 Skincare Technologies: GS Regenerative Medical and Beauty Services Ltd held 50 percent of the shares, while the respondent, Denise Marston, held the other 50 percent. Under the sale terms, Marston agreed to acquire all shares and the registered JU22 trademark — with trademark registrations confirmed in Europe, England, Albania and Turkey — together with exclusive scientific study rights related to the cosmetic product line. The agreed cash consideration for the shares stood at €80,000, with a deadline of December 31, 2024.

The transfer also included a product consideration: Marston was to supply specific quantities of existing stock as partial payment — 410 boxes of night cream, 350 boxes of eye contour cream, 450 boxes of dark spot cream, and 390 boxes of PRP creams — valued at €11,094 according to the initial agreement. By the time of the judicial protest, the plaintiffs stated only €12,500 of the cash price had been paid, leaving €67,500 outstanding plus legal interest calculated at 8 percent. The plaintiffs also claimed the stock payment had not been delivered and placed a figure of €78,594 as outstanding for the stock, again plus 8 percent interest. That figure differs from the earlier stated €11,094 stock valuation and may reflect revaluation, additional costs, or accumulated interest and expenses; the judicial protest is the plaintiffs’ formal step to preserve their rights while they seek a judicial remedy.

The complaint accuses Marston of continuing to use and promote JU22 products at her clinic in Birkirkara, despite failing to complete payments. GS Regenerative describes this conduct as “wholly irresponsible, negligent and unacceptable,” claiming she lacks the required consent to use the trademark and to promote the cosmetic line. The judicial protest warns that continued non‑performance may prompt court applications for warrants — a term likely referring to orders preventing the respondent from using the trademark and brand pending resolution.

How trademark ownership affects control over products and sales

A registered trademark confers the exclusive right to use a sign to distinguish goods or services within the territories where it is registered. The parties here noted registrations in multiple jurisdictions: the European Union, the United Kingdom, Albania and Turkey. That geographic spread matters. Rights granted by each registration enable the owner to prevent third parties from marketing identical or confusingly similar goods under the same mark in those territories.

When trademarks and company shares change hands, the sale agreement must be precise about what is being transferred:

Is the trademark being assigned outright, or is a license being granted?
Does the assignment include associated goodwill, manufacturing know‑how, scientific studies and product formulations?
What representations and warranties cover the scope and validity of the trademark rights?
Which territories are included in the transfer?

Failure to clarify these points invites disputes. If the seller intends to retain some rights or the right to use existing stock, the agreement should expressly provide for that. Conversely, the buyer must secure not only the registered trademark but also control over branded inventory and any clinical or study data necessary to substantiate claims about the products.

In this case, the plaintiffs assert that the JU22 trademark and scientific study rights belong to the surgeon and company until the buyer fulfills her payment obligations. That position relies on contractual terms: if the sale was conditional on full payment and those conditions were not satisfied, the plaintiffs may argue ownership did not pass.

Judicial protest and immediate remedies: what the plaintiffs can realistically pursue

A judicial protest functions as a formal written notice documenting a party’s claim and notifying the other side that legal action will follow if obligations are not honored. Its exact legal effect varies across jurisdictions. Here, the protest serves three practical functions:

It puts the respondent on clear written notice of the plaintiffs’ position and the amounts claimed, creating a record that may be used in subsequent court proceedings.
It preserves evidence of the plaintiffs’ demands and the respondent’s alleged conduct, which can be important for interim relief applications.
It signals the plaintiffs’ intent to seek court orders to prevent further use of the trademark and to enforce contractual obligations.

If the plaintiffs pursue an urgent court order, typical remedies in disputes over brand use and unpaid purchase price include:

Interim injunctions restraining the respondent from using the trademark, selling the products, or promoting the brand pending final determination.
Attachment or seizure orders to preserve stock and prevent dissipation of assets.
Orders directing specific performance, compelling the buyer to fulfill contractual obligations where monetary damages are inadequate.
Declaratory relief to establish the true owner of the trademark and the rights attached to it.
Claims for unpaid purchase price plus interest and costs.

Courts weigh several factors when deciding whether to grant interim relief: the strength of the plaintiff’s prima facie case, the risk of irreparable harm if interim relief is refused, and the balance of convenience between the parties. Evidence that the respondent continues to sell or promote allegedly owned products tends to strengthen a plaintiff’s argument that immediate intervention is necessary to protect the brand and prevent dilution or reputational damage.

Stock, payment mechanics and retention of title: why the numbers matter

Sales of businesses or brands frequently involve both cash consideration and transfers of existing stock. The contract should state who owns the stock during the payment period and whether ownership of inventory transfers immediately or upon final settlement of the agreed sums.

Retention of title clauses are commonly used to protect sellers. These clauses state that legal ownership of goods remains with the seller until the buyer pays in full. If a retention clause was included and properly drafted, the seller maintains title to the stock and has the legal right to reclaim it if the buyer defaults. If no such clause exists, the seller may need to rely on other legal remedies or prove that title did not transfer due to the buyer’s failure to satisfy agreed conditions.

The divergence between the stock figure in the agreement (€11,094) and the amount listed as outstanding (€78,594) in the judicial protest deserves careful scrutiny. Possible explanations include:

A clerical error in the protest or in the initial reporting.
The plaintiffs’ adjusted valuation of stock after reappraisal.
Inclusion of additional unpaid invoices, costs of storage or transport, and interest in the larger figure.
Aggregation of multiple outstanding sums into a single line item.

Accurate accounting and clear contractual specification of stock valuation, delivery terms, invoicing and default consequences would avoid such disagreements. When stock forms part of the consideration, parties should specify how and when the inventory will be transferred, who bears the risk of loss, and what happens if the buyer cannot deliver or defaults.

Why clinical settings and cosmetics elevate reputational risk

Cosmetic and aesthetic products sold through clinics carry reputational as well as regulatory risks. A medical professional’s clinic adds a layer of trust for patients. When a dispute arises over ownership or authorization to sell a branded product used in clinical settings, consequences can include:

Erosion of patient trust if products suddenly become unavailable or are subject to litigation.
Regulatory scrutiny if product claims misalign with scientific evidence or if study rights are contested.
Potential liability if a party continues promoting a product after the seller rescinds authorization and the product causes adverse effects.

Clinics that use or sell branded cosmetics should ensure clarity about supply chains and authorization. Agreements should address whether clinicians are permitted to continue selling branded stock during ownership transitions and whether they can make clinical claims based on previously conducted scientific studies. The plaintiffs’ allegation that the respondent continued to use and promote JU22 products at her Birkirkara clinic underscores how brand disputes can spill into professional and reputational domains.

Likely legal paths and timelines

After a judicial protest, plaintiffs typically select one or more paths:

Apply for an urgent interlocutory injunction to prevent the respondent from using the trademark or selling the products while the dispute is litigated.
File a civil action for breach of contract and seek judgment for unpaid sums plus interest and costs.
Seek a declaratory judgment on ownership of the trademark and associated rights.
Where goods are at risk of removal or dissipation, apply for attachment or preservation orders.

Timelines depend on jurisdictional procedures. Emergency interim relief hearings can occur within days or weeks, while a full trial may take months to more than a year. Courts typically require the applicant to provide supporting affidavits and documentation: the share purchase agreement, trademark registration certificates, invoices, correspondence demanding payment, and evidence of the respondent’s continued use of the brand.

If the court grants an injunction, relief can be immediate and decisive: the respondent may be ordered to stop all sales and promotion under penalty of contempt. If the court later finds the plaintiffs’ case weak, it can dissolve the injunction and order costs accordingly. For the defendant, resisting an injunction is risky when the claimant presents persuasive documentary evidence and an ongoing threat to the brand.

Commercial and reputational consequences for both parties

For the seller/plaintiff:

A successful injunction preserves brand integrity and prevents unauthorized sales.
Winning a judgment for unpaid sums recovers lost revenue and enforces the sale terms.
Aggressive legal steps risk reputational exposure for pursuing a former co-owner or clinician.

For the buyer/respondent:

Continued use of the brand pending resolution can lead to contempt orders and damages.
If found liable for wrongful use, the respondent may have to cease sales, surrender stock or pay damages, and cover the plaintiffs’ legal costs.
Even if ultimately vindicated, interim restrictions can cause lost sales and harm professional relationships.

Third parties—retailers, distributors, patients—also face uncertainty. Retailers holding stock may find themselves facing conflicting claims; consumers who purchased products could be left unsure about warranties, refunds or product safety assurances.

Preventive steps companies and prospective buyers should take

Disputes like this are preventable through careful contracting and sound commercial practice. Recommended precautions:

Comprehensive sale agreement:
- Specify whether the transaction is a transfer of shares, assets, or both.
- Clearly assign trademark registrations, specify territories, and set out the mechanics of assignment filings.
- Include representations and warranties about validity of IP, encumbrances, pending litigation and product compliance.
Clear terms for stock and inventory:
- State whether ownership of existing stock transfers on signing or on completion.
- Use retention of title clauses to protect sellers when payments are staged.
- Record stock counts, batch numbers and quality control certificates at the time of sale.
Escrow and staged payments:
- Use an escrow agent for cash consideration or registrar for transferring trademark on condition of cleared funds.
- Consider staged transfer of shares with milestones tied to payments.
Due diligence on commercial use:
- Verify how the buyer will market products and whether current distribution channels (clinics, online retailers) will remain authorized.
- Check whether clinics or clinicians have licenses or authorizations to continue sales and whether those rights bind to a new owner.
Transitional and non-compete provisions:
- Include clauses that regulate who may sell products during the transfer period to avoid parallel marketing or dilution.
Dispute resolution clauses:
- Define governing law, jurisdiction and preferred methods of dispute resolution. Consider arbitration for speed and confidentiality.
Insurance and recall planning:
- Ensure product liability and product recall insurance is in place in case disputes trigger supply interruptions or adverse events.

Implementing these measures makes it less likely that a transaction will unravel and more straightforward to resolve disputes that do arise.

Cross-border trademark registrations: scope and enforcement challenges

The JU22 trademark is reported as registered in the EU, the UK, Albania and Turkey. Each registration is siloed under the intellectual property laws of that jurisdiction. Enforcement therefore requires action in the specific territory where infringement occurs. A few practical implications:

Territorial enforcement: A court order in one country will not automatically bind third parties in another unless reciprocal enforcement mechanisms exist. A global brand owner must be prepared to bring parallel actions or coordinate enforcement across jurisdictions.
Differences in substantive law: Trademark laws vary. Evidence required to prove infringement or to obtain interim relief differs, as do procedures and timelines.
Registration maintenance: Trademarks require upkeep—renewals, proof of use and opposition management. A buyer should ensure record transfer at the respective trademark offices to avoid disputes about who has the administrative authority to enforce rights.
Customs and border measures: Registered marks can be used to request customs authorities to detain counterfeit or disputed goods at borders; the effectiveness of these tools depends on local practice.

Where sale agreements cross borders, seller and buyer should specify where trademark assignments will be recorded, who bears the costs of recordal, and how enforcement will be coordinated if a dispute arises.

Practical steps for clinics, retailers and consumers who face a brand dispute

Clinics and retailers:

Pause new marketing that claims rights or exclusivities the business no longer holds.
Isolate and document existing stock—batch numbers, purchase invoices and the dates of receipts—so that ownership and origin can be traced if required.
Communicate clearly with suppliers and the brand owner to understand legal positions before continuing sales.
Avoid selling contested stock if there is clear written notice from a rights holder claiming unauthorized use; this reduces exposure to secondary liability.

Consumers and patients:

Keep purchase records and consult the seller about warranty or return policies.
If products are subject to safety concerns, report adverse events to health authorities regardless of legal disputes between commercial parties.
Ask for clarification and receipts when clinicians sell branded products in-clinic, including confirmation of product authenticity and origin.

How courts balance rights: sample legal considerations

When an applicant seeks interim relief to stop a respondent using a trademark or selling products, courts typically examine:

The strength of the applicant’s legal title or contractual entitlement.
Whether the applicant would suffer irreparable harm that monetary damages cannot remedy, such as brand dilution or loss of goodwill.
The potential harm to the respondent if an injunction is granted but later shown to be unnecessary.
Public interest considerations, for example where product availability affects patients.

Documentary evidence is decisive. An executed sale agreement with explicit conditional transfer clauses, invoices showing unpaid sums, correspondence ordering compliance, and proof of ongoing sales by the respondent create a persuasive record.

Possible defenses and counterarguments the respondent may raise

A respondent in this scenario might advance any of the following defenses:

Payment has been made or part-performance should be credited against obligations.
The agreement permitted ongoing use or provided a license to use the trademark pending full transfer.
The plaintiffs waived enforcement or accepted partial payments as final settlement.
The trademark assignment had already been completed, or the transfer of shares gave the respondent control independent of cash payments due.
There are genuine disputes over valuation of stock or the interpretation of contractual language.

Each defense requires corroborating evidence: bank receipts, contemporaneous emails, minutes of meetings, and signed amendment agreements. Courts scrutinize conduct after the agreement was signed. If the seller continued to permit use of the brand at the clinic or engaged in inconsistent behavior, the respondent might argue estoppel or waiver.

Negotiation and settlement options that can resolve the matter quickly

Litigation is costly and time-consuming. Parties often settle using carefully tailored arrangements. Common settlement options include:

Restructured payment plan with escrow for future sums and an interim license allowing controlled use of the trademarks until full payment.
Return or sequestering of branded stock in exchange for release of some claims.
Mediated settlement that splits disputed valuations of stock and includes confidentiality terms to limit reputational impact.
Conditional assignment where the buyer receives the trademark immediate title once escrowed funds clear, plus undertakings about marketing channels.

Mediation or direct negotiation can preserve business relationships, protect brand continuity for customers, and avoid public fights that damage both parties’ reputations.

What this case signals to investors and brand managers in the cosmetics sector

This dispute underlines a few market realities:

Cosmetic brands tied to clinicians have intangible value associated with professional endorsement; losing control over that endorsement damages market position.
Formalizing transfers matters as much as the headline price. Ambiguities in stock valuation, payment mechanics and rights to use scientific study data invite disputes.
Cross-border brand builds require careful intellectual property portfolio management and clear protocols for recordal and enforcement across jurisdictions.

Investors and managers must treat skincare and aesthetic brands as both clinical and consumer-facing assets and structure deals accordingly. This means legal teams and commercial negotiators should work together from day one to align contract mechanics with market realities.

Checklist: drafting a sale agreement for a clinical skincare brand

Use the following as a drafting checklist:

Define the structure: share sale, asset sale, or mix.
Identify all IP to be transferred: trademarks, trade names, domain names, scientific studies, formulations.
Set territory and scope for each IP right.
Specify consideration: cash, stock, services, contingent payments, and valuation methods.
Detail stock/inventory mechanics: valuation, transfer date, retention of title, risk allocation.
State who bears costs of trademark recordal and renewals.
Include representations and warranties about regulatory compliance, product safety and authorizations for clinical claims.
Provide indemnities for past claims and product liability.
Establish escrow or bank guarantees for payment security.
Include dispute resolution and governing law clauses.
Plan transitional services: supply, marketing, and distribution continuity.
Consider confidentiality and non‑disparagement clauses to protect brand reputation post-transaction.

Final observations on risk management and reputational stewardship

Disputes over brand ownership rarely remain confined to legal papers. They reach social media, patient forums and retail shelves. Parties should coordinate legal responses with communications strategies that make measured disclosures to safeguard customer confidence while fulfilling legal obligations to preserve evidence and assert rights.

Proper legal drafting, thorough due diligence, and use of escrow or conditional transfer mechanisms prevent many of the common failures that lead to cases such as the JU22 dispute. When a conflict does arise, swift, evidence‑based legal steps focused on preserving assets and limiting reputational fallout offer the best path back to commercial normality.

FAQ

Q: What exactly is a judicial protest and what does it accomplish? A: A judicial protest is a formal legal notice documenting a claimant’s assertions and signaling intent to pursue judicial remedies. It preserves a written record of the claim and can support applications for interim court relief, such as injunctions, but does not itself decide the dispute.

Q: Can a seller prevent a buyer from promoting products after a share-sale agreement is signed? A: It depends on contract terms. If the sale is conditional on full payment and the agreement reserves title or license rights pending payment, the seller can lawfully restrict the buyer’s promotional rights. Courts will examine the agreement’s wording and parties’ conduct to determine who holds legitimate rights at any given time.

Q: What immediate legal remedies are available to protect a trademark? A: Remedies include interim injunctions to stop unauthorized use, seizure or preservation orders for inventory, declaratory relief on ownership and claims for damages. Urgent relief requires credible evidence that the trademark owner’s rights are being infringed and that irreparable harm is likely.

Q: Why are cross-border trademark registrations important in these disputes? A: Trademark rights are territorial. Registration in each market gives the owner enforcement tools within that jurisdiction. If the disputed brand is marketed in multiple countries, an owner may need coordinated enforcement strategies across those jurisdictions.

Q: Should sellers rely on retention of title clauses? A: Retention of title clauses are a powerful protection if properly drafted and enforceable under local law. They allow sellers to retain legal ownership of goods until payments are made and can provide a basis to reclaim stock if the buyer defaults.

Q: What steps should clinics take if they are selling a disputed brand? A: Clinics should stop further promotions until they understand the legal position, inventory and document stock, communicate with their supplier and seek legal advice to minimize exposure. Continuing sale after receiving a clear legal notice can increase legal risk.

Q: How can parties avoid disputes when transferring cosmetic brands? A: Use precise contracts that cover IP transfer, stock handling, escrow for payments, representations on regulatory compliance, and clear dispute resolution clauses. Conduct thorough due diligence on trademarks, regulatory history and contractual obligations tied to clinical endorsements.

Q: If a court issues an injunction, can the defendant still sell the products later? A: If an injunction is interim, the defendant may be restrained temporarily. The ultimate ability to sell depends on the final judgment. If the defendant prevails, the injunction may be lifted; if the claimant prevails, the defendant may be permanently barred or required to account for proceeds and pay damages.

Q: What role do scientific study rights play in a cosmetics sale? A: Scientific study rights underpin product safety and efficacy claims. Ownership or licensed use of these studies affects marketing claims, regulatory compliance and the ability to substantiate promotional statements. Buyers should secure rights to any studies necessary for ongoing commercialization.

Q: Is mediation a viable option to resolve such disputes? A: Yes. Mediation often resolves commercial disputes more quickly and confidentially than litigation. It allows the parties to craft flexible solutions—payment plans, stock returns, interim licenses—that preserve business relationships and reduce public reputational harm.